NICE wants more data for lung cancer treatment Iressa
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has asked AstraZeneca for more information about its Iressa (gefitinib) for treating non-small-cell lung cancer (NSCLC). Meanwhile, the firm's submission to NICE marks a first for patient access schemes.